Latest Articles

  • Skin and soft-tissue infections: Classifying and treating a spectrum
    Sabitha Rajan, MD, MSc, FHM
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 57-66; DOI: https://doi.org/10.3949/ccjm.79a.11044
  • Cytomegalovirus colitis
    Jana G. Hashash, MD, Marwan Refaat, MD, Abdulrahman Abdulbaki, MD, Elie G. Aoun, MD and Leonard Baidoo, MD
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 12-13; DOI: https://doi.org/10.3949/ccjm.78a.11028
  • Correction
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 78; DOI: https://doi.org/10.3949/ccjm.79c.01001
  • Should target natriuretic peptide levels be used for outpatient management of chronic heart failure?
    Ahmed Ibrahim, MD, Motaz Baibars, MD, M. Chadi Alraies, MD, FACP and Guilherme H. Oliveira, MD
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 22-25; DOI: https://doi.org/10.3949/ccjm.79a.11066
  • Updates in the medical management of Parkinson disease
    Hubert H. Fernandez, MD
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 28-35; DOI: https://doi.org/10.3949/ccjm.78gr.11005

    Most, if not all, currently available drugs for Parkinson disease address dopaminergic loss and relieve symptoms. However, their adverse effects can be limiting and they do not address disease progression. Moreover, nonmotor features of Parkinson disease such as depression, dementia, and psychosis are now recognized as important and disabling. A cure remains elusive. However, promising interventions and agents are emerging. As an example, people who exercise regularly are less likely to develop Parkinson disease, and if they develop it, they tend to have slower progression.

  • Addressing disparities in health care
    Charles S. Modlin, MD, MBA
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 44-45; DOI: https://doi.org/10.3949/ccjm.79a.11167
  • Is niacin ineffective? Or did AIM-HIGH miss its target?
    Stephen J. Nicholls, MBBS, PhD
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 38-43; DOI: https://doi.org/10.3949/ccjm.79a.11166

    The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (Niaspan). In fact, there was a trend toward a greater risk of ischemic stroke, which did not reach statistical significance. But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group.

  • Bugs, pundits, evolution, and the New Year
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine January 2012, 79 (1) 10; DOI: https://doi.org/10.3949/ccjm.79b.12001
  • A 54-year-old woman with pancytopenia
    Andrew D. Timothy, DO, MS, Armin Jegalian, MD, PhD and Alan E. Lichtin, MD
    Cleveland Clinic Journal of Medicine December 2011, 78 (12) 815-820; DOI: https://doi.org/10.3949/ccjm.78a.11061

    Her red blood cell, white blood cell, and platelet counts are all low. What is the cause?

  • A less common source of dyspnea in scleroderma
    Faysal Altahawi and M. Chadi Alraies, MD, FACP
    Cleveland Clinic Journal of Medicine December 2011, 78 (12) 801-802; DOI: https://doi.org/10.3949/ccjm.78a.11014

    A 48-year-old man with scleroderma reports progressive shortness of breath, fatigue, and melena over the past month. What is the link?

Pages